Genmab A/S (LTS:0MGB)
kr 1839.5 -9.25 (-0.5%) Market Cap: 117.16 Bil Enterprise Value: 88.58 Bil PE Ratio: 22.31 PB Ratio: 3.70 GF Score: 88/100

Genmab A/S 2019 R&D Update and ASH Data Review Meeting Transcript

Dec 10, 2019 / 01:00AM GMT
Release Date Price: kr1579 (+0.22%)
Jan G. J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

All right. So good evening. Welcome to those of you who are with us here in person in Orlando and those of you participating via the webcast. As usual, we have a couple of quick housekeeping notices before we begin this year's event. So the slides from tonight's presentation will be available for download in PDF format on our website immediately after the event. And so there will also be an archive of this webcast available later this evening if you would like to relive tonight's presentations and Q&A.

We will also be holding multiple Q&A sessions towards this evening. And if you are participating on the webcast and would like to ask a question, that is simple because you then click "Ask A Question" button located above the slides and then type in your question and click submit. For those of you in the room, you will notice that we are also videotaping tonight's events and this recording is only for internal use at Genmab, and will not be shown externally.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot